EML4 and non-small cell lung carcinoma: Further, a preclinical evaluation of PF-06463922 displayed increased potency against acquired NSCLC ALK resistance mutations, with regression of EML4-ALK-driven brain metastases, and within the safety margins in a variety of preclinical studies (Johnson et al., 2014; Zou et al., 2015).